<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:hpo ids='HP_0012115'>Hepatitis</z:hpo>-associated <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> is a common syndrome in patients with <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, <z:hpo ids='HP_0012115'>hepatitis</z:hpo>-associated <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> is an <z:mpath ids='MPATH_194'>immune-mediated disease</z:mpath> that does not appear to be caused by any of the known <z:hpo ids='HP_0012115'>hepatitis</z:hpo> viruses including <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C virus </plain></SENT>
<SENT sid="2" pm="."><plain>In addition, to the best of our knowledge there are no reported cases of patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C <z:e sem="disease" ids="C0042769" disease_type="Disease or Syndrome" abbrv="">virus infection</z:e> developing <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> associated with pegylated interferon alpha 2a treatment </plain></SENT>
<SENT sid="3" pm="."><plain>CASE PRESENTATION: We report the case of a 46-year-old Greek man who developed severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> during treatment with pegylated interferon alpha 2a for <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C <z:e sem="disease" ids="C0042769" disease_type="Disease or Syndrome" abbrv="">virus infection</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>He presented with generalized <z:hpo ids='HP_0000979'>purpura</z:hpo> and <z:mp ids='MP_0009275'>bruising</z:mp>, as well as <z:hpo ids='HP_0000980'>pallor</z:hpo> of the skin and mucous membranes </plain></SENT>
<SENT sid="5" pm="."><plain>His blood tests showed <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>He underwent allogeneic bone marrow transplantation after completing two courses of immunosuppressive therapy with antithymocyte globulin and <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: The combination of a specific environmental precipitant represented by the <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C <z:e sem="disease" ids="C0042769" disease_type="Disease or Syndrome" abbrv="">virus infection</z:e>, an altered metabolic detoxification pathway due to treatment with pegylated interferon alpha 2a and a facilitating genetic background such as polymorphism in metabolic detoxification pathways and specific human leukocyte antigen genes possibly conspired synergistically in the development of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> in this patient </plain></SENT>
<SENT sid="8" pm="."><plain>Our case clearly shows that the causative role of pegylated interferon alpha 2a in the development of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> must not be ignored </plain></SENT>
</text></document>